TARA News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

TA

Mkt Cap

$137.1M

Volume

1.05M

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBCProtara Therapeutics reported positive 12-month efficacy and safety data from its Phase 2 ADVANCED-2 trial of TARA-002 in BCG-naïve non-muscle invasive bladder cancer patients, demonstrating a 55% complete response rate at 12 months with no Grade 3 or greater adverse events. The company plans to initiate the registrational ADVANCED-3 trial in the second half of 2026 and submit a BLA for TARA-002 in lymphatic malformations in 2H 2027.GlobeNewswire Inc. · May 15, 2026

Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business UpdateProtara Therapeutics reported Q4 2025 results with a net loss of $17.3 million ($0.37 per share) and full-year loss of $57.4 million ($1.34 per share). The company announced interim data from its ADVANCED-2 trial showing TARA-002 achieved a 68% complete response rate at six months in BCG-Unresponsive bladder cancer patients with a favorable safety profile. Protara expects to complete enrollment of the BCG-Unresponsive cohort in H2 2026 and initiate the ADVANCED-3 trial in BCG-Naïve patients in H2 2026. The company also received Breakthrough Therapy and Fast Track designations for TARA-002 in lymphatic malformations. With $197.9 million in cash and equivalents, Protara expects to fund operations into 2028.GlobeNewswire Inc. · Mar 10, 2026

Protara Therapeutics to Participate in Upcoming Investor ConferencesProtara Therapeutics announced participation in two upcoming investor conferences in February and March 2026, where management will hold fireside chats. The company also plans to present updated interim data from its Phase 2 ADVANCED-2 trial of TARA-002 for BCG-unresponsive non-muscle invasive bladder cancer patients at the ASCO Genitourinary Cancers Symposium.GlobeNewswire Inc. · Feb 19, 2026

Protara Announces Pricing of $75 Million Public OfferingProtara Therapeutics plans to raise approximately $75 million through a public offering of 13,043,479 common stock shares at $5.75 per share, with proceeds intended to fund clinical development of TARA-002 and other programs.GlobeNewswire Inc. · Dec 5, 2025

Protara Announces Proposed Public OfferingProtara Therapeutics plans to raise $75 million through a public offering of common stock and pre-funded warrants. The proceeds will fund clinical development of TARA-002 and other clinical programs, with J.P. Morgan, TD Cowen, and Piper Sandler acting as joint book-running managers.Benzinga · Dec 4, 2025

Protara Beats Q2 Loss EstimatesProtara Therapeutics reported a Q2 2025 net loss of $15.0 million, with no revenue but continued progress in clinical trials for TARA-002 and IV Choline Chloride. The company maintains $145.6 million in cash reserves, projecting operational funding into mid-2027.The Motley Fool · Aug 11, 2025

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBCProtara Therapeutics announced positive interim results from its ongoing Phase 2 ADVANCED-2 trial of TARA-002, its investigational cell-based therapy, in patients with high-risk non-muscle invasive bladder cancer (NMIBC). The results showed high complete response rates and a favorable safety profile.GlobeNewswire Inc. · Apr 26, 2025

Protara Highlights Recent Updates and Anticipated 2025 MilestonesProtara Therapeutics reported positive interim results from its ADVANCED-2 trial of TARA-002 in non-muscle invasive bladder cancer (NMIBC) patients. The company also expects to begin a pivotal trial for IV Choline Chloride and report data from its STARBORN-1 trial of TARA-002 in lymphatic malformations in 2025.GlobeNewswire Inc. · Jan 13, 2025

Protara Announces Pricing of $100 Million Public OfferingProtara Therapeutics announced the pricing of a $100 million public offering, with plans to use the proceeds to fund the clinical development of TARA-002 and other programs.GlobeNewswire Inc. · Dec 10, 2024

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic OncologyProtara Therapeutics announced that data from an interim analysis of the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC) will be presented at the upcoming Society of Urologic Oncology meeting. The trial is evaluating the safety and anti-tumor activity of TARA-002 in NMIBC patients.GlobeNewswire Inc. · Nov 15, 2024

TA

TARAProtara Therapeutics, Inc. Common Stock

TARA

Pay with—

Available Balance0.00

Your PositionYou don't own any TARA yet.

Related Tickers

Earnings